top of page

NEUWERK advises Secarna Pharmaceuticals on License Agreement with Achilles Therapeutics

Hamburg - On November 10, 2011, Secarna Pharmaceuticals, a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies, announced it has concluded a research, development and license agreement to develop optimized T cell therapies with Achilles Therapeutics.

Under the terms of the agreement, Secarna will employ its commercially validated discovery and development platform, LNAplus™, to generate ASO candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized T cell therapies being developed by Achilles. Following in vitro testing performed by Secarna, Achilles will conduct production feasibility and optimization testing.

Secarna will receive an undisclosed upfront payment, a target-based technology access fee as well as option exercise fees. Secarna is also eligible to receive development and commercial milestone payments as well as tiered royalties on net sales of personalized T cell therapies developed and commercialized under this collaboration.

NEUWERK advised Secarna on the transaction.

For more information, please see Secarna's press release.

About Secarna Pharmaceuticals:

Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology, immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies. With over 15 development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities.

Advisors for Secarna Pharmaceuticals: NEUWERK, Hamburg Börge Seeger, MLE, JSM, CLP (transaction lead, partner) Dr. Jonas Welge (Associate)

About NEUWERK: NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.

Press contact: For further questions please contact Dr. Sebastian Naber (, T +49 40 340 5757-30.

NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany


bottom of page